At a glance
ClinicalIndex Comparison RecordN/ACompleted· 11 enrolled
Drug / intervention
Cytosine Arabinosidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia
In Brief
A clinical study evaluating Cytosine Arabinoside for Acute Myeloid Leukemia. Completed, enrolled 11 participants across 1 site.
Detailed Summary
High-dose cytarabine (HiDAC) is considered a standard chemotherapy treatment for patients with acute myeloid leukemia. However, most patients receiving this therapy are required to be admitted to the hospital during their treatment course. The purpose of this study is to compare the safety and cost of high-dose cytarabine treatment given in an in-patient setting versus an out-patient setting.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2011
First PostedApr 2014
Primary CompletionDec 2014
Study CompletionAug 2017
TodayJul 2026
First PostedApr 2, 2014
Enrollment StartMay 1, 2011
Primary CompletionDec 1, 2014
Study CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 12.3 years ago
Interventions
Cytosine Arabinosidedrug